The results revealed a positive correlation between IGF2BP2 mRNA expression and key drug‐resistant markers, including ABCC1,41, 42 ABCC3,43, 44 GSPT1,45 and MGMT46 (Figure 5A), which implied the connection between IGF2BP2 expression and drug resistance within glioma. This evidence concerns the gene IGF2BP2 and central nervous system cancer.